Rosiglitazone induces cardiotoxicity by accelerated apoptosis

Cardiovascular Toxicology

Volumn 14, Issue 2, 2014, Pages 99-119

  Mishra, Pratibha ^a   Singh, Sarvendra Vikram ^a   Verma, Ajeet Kumar ^a   Srivastava, Pallavi ^a   Sultana, Sarwat ^b   Rath, Srikanta Kumar ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Cardiomyocyte; Cardiotoxicity; db db mice; Rosiglitazone

Indexed keywords

CATALASE; CREATINE KINASE MB; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; HEME OXYGENASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; PROTEIN KINASE C DELTA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROSIGLITAZONE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR NRF2; TROPONIN T; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; HEME OXYGENASE; HMOX1 PROTEIN, RAT; NFE2L2 PROTEIN, RAT; NITRIC OXIDE SYNTHASE; PRKCD PROTEIN, RAT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL DIFFERENTIATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIABETES MELLITUS; GENE EXPRESSION; HEART MUSCLE CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NICK END LABELING; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RESPIRATORY CHAIN; ANIMAL; BLOOD; CELL LINE; CELL SURVIVAL; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEART DISEASE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; SIGNAL TRANSDUCTION; TIME; TOXICITY;

MUS; RATTUS;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HEART DISEASES; HEME OXYGENASE (DECYCLIZING); HYPOGLYCEMIC AGENTS; MALE; MICE; MYOCYTES, CARDIAC; NADPH OXIDASE; NF-E2-RELATED FACTOR 2; NITRIC OXIDE SYNTHASE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PROTEIN KINASE C-DELTA; RATS; SIGNAL TRANSDUCTION; SUPEROXIDES; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 84902368549     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-013-9234-y     Document Type: Article

References (40)

1. Kim, H. S., Hwang, Y. C., Koo, S. H., Park, K. S., Lee, M. S., Kim, K. W., et al. (2013). PPAR-gamma activation increases insulin secretion through the up-regulation of the free fatty acid receptor GPR40 in pancreatic beta-cells. PLoS ONE, 8, e50128.
2. Semple, R. K., Chatterjee, V. K., & O'Rahilly, S. (2006). PPAR gamma and human metabolic disease. The Journal of Clinical Investigation, 116, 581-589. (Pubitemid 43326862)
3. Mohanty, P., Aljada, A., Ghanim, H., Hofmeyer, D., Tripathy, D., Syed, T., et al. (2004). Evidence for a potent antiinflammatory effect of rosiglitazone. The Journal of Clinical Endocrinology and Metabolism, 89, 2728-2735.
4. Hasegawa-Moriyama, M., Ohnou, T., Godai, K., Kurimoto, T., Nakama, M., & Kanmura, Y. (2012). Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuates postincisional pain by regulating macrophage polarization. Biochemical and Biophysical Research Communication, 426, 76-82.
5. Nissen, S. E., & Wolski, K. (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine, 356, 2457-2471. (Pubitemid 46919772)
6. Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., et al. (2007). Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. New England Journal of Medicine, 357, 28-38. (Pubitemid 47026732)
7. Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., et al. (2009). Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, openlabel trial. Lancet, 373, 2125-2135.
8. Nissen, S. E., & Wolski, K. (2010). Rosiglitazone revisited: An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. JAMA Internal Medicine, 170, 1191-1201.
9. Wilson, K. D., Li, Z., Wagner, R., Yue, P., Tsao, P., Nestorova, G., et al. (2008). Transcriptome alteration in the diabetic heart by rosiglitazone: Implications for cardiovascular mortality. PLoS ONE, 3, e2609.
10. Zhou, M., Xu, A., Lam, K. S., Tam, P. K., Che, C. M., Chan, L., et al. (2010). Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin. Journal of Hepatology, 53, 1108-1116.
11. Plumb, J. A., Milroy, R., & Kaye, S. B. (1989). Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Research, 49, 4435-4440. (Pubitemid 19208340)
12. Sieuwerts, A. M., Klijn, J. G., Peters, H. A., & Foekens, J. A. (1995). The MTT tetrazolium salt assay scrutinized: How to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival. European Journal of Clinical Chemistry and Clinical Biochemistry, 33, 813-823.
13. Maruyama, S., Shibata, R., Ohashi, K., Ohashi, T., Daida, H., Walsh, K., et al. (2012). Adiponectin ameliorates doxorubicin-induced cardiotoxicity through Akt protein-dependent mechanism. Journal of Biological Chemistry, 286, 32790-32800.
14. Cai, J., & Jones, D. P. (1998). Superoxide in apoptosis. Mitochondrial generation triggered by cytochrome c loss. Journal of Biological Chemistry, 273, 11401-11404. (Pubitemid 28272028)
15. Ferre, P. (2004). The biology of peroxisome proliferator-activated receptors: Relationship with lipid metabolism and insulin sensitivity. Diabetes, 53, S43-S50.
16. Lebovitz, H. E., Dole, J. F., Patwardhan, R., Rappaport, E. B., & Freed, M. I. (2001). Rosiglitazone monotherapy is effective in patients with type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism, 86, 280-288. (Pubitemid 32109807)
17. The Dream Trial Investigators. (2011). Incidence of diabetes following Ramipril or Rosiglitazone withdrawal. Diabetes Care, 34, 1265-1269.
18. Arola, O. J., Saraste, A., Pulkki, K., Kallajoki, M., Parvinen, M., & Voipio-Pulkki, L. M. (2000). Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Research, 60, 1789-1792. (Pubitemid 30207630)
19. Ito, H., Shimojo, T., Fujisaki, H., Tamamori, M., Ishiyama, S., Adachi, S., et al. (1999). Thermal preconditioning protects rat cardiac muscle cells from doxorubicin-induced apoptosis. Life Sciences, 64, 755-761. (Pubitemid 29098970)
20. Byrne, J. A., Grieve, D. J., Bendall, J. K., Li, J. M., Gove, C., Lambeth, J. D., Cave, A. C., & Shah, A. M. (2003). Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circulation Research, 93, 802-805.
21. Cave, A. C., Brewer, A. C., Narayanapanicker, A., Ray, R., Grieve, D. J., Walker, S., et al. (2006). NADPH oxidases in cardiovascular health and disease. Antioxidants & Redox Signaling, 8, 691-728. (Pubitemid 44043102)
22. Park, J. W., Ma, M., Ruedi, J. M., Smith, R. M., & Babior, B. M. (1992). The cytosolic components of the respiratory burst oxidase exist as a M(r) approximately 240,000 complex that acquires a membrane-binding site during activation of the oxidase in a cellfree system. Journal of Biological Chemistry, 267, 17327-17332.
23. Vignais, P. V. (2002). The superoxide-generating NADPH oxidase: Structural aspects and activation mechanism. Cellular and Molecular Life Sciences, 59, 1428-1459.
24. Wientjes, F. B., Hsuan, J. J., Totty, N. F., & Segal, A. W. (1993). p40phox, a third cytosolic component of the activation complex of the NADPH oxidase to contain src homology 3 domains. Biochemical Journal, 296(Pt 3), 557-561.
25. Looi, Y. H., Grieve, D. J., Siva, A., Walker, S. J., Anilkumar, N., Cave, A. C., et al. (2008). Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension, 51, 319-325. (Pubitemid 351159945)
26. Varin, R., Mulder, P., Richard, V., Tamion, F., Devaux, C., Henry, J. P., et al. (1999). Exercise improves flow-mediated vasodilatation of skeletal muscle arteries in rats with chronic heart failure. Role of nitric oxide, prostanoids, and oxidant stress. Circulation, 99, 2951-2957. (Pubitemid 29258985)
27. Haywood, G. A., Tsao, P. S., von der Leyen, H. E., Mann, M. J., Keeling, P. J., Trindade, P. T., et al. (1996). Expression of inducible nitric oxide synthase in human heart failure. Circulation, 93, 1087-1094. (Pubitemid 26087012)
28. Singh, P., Mishra, S. K., Noel, S., Sharma, S., & Rath, S. K. (2012). Acute exposure of apigenin induces hepatotoxicity in Swiss mice. PLoS ONE, 7, e31964.
29. Habig, W. H., Pabst, M. J., & Jakoby, W. B. (1974). Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. Journal of Biological Chemistry, 249, 7130-7139.
30. Sekhar, K. R., Crooks, P. A., Sonar, V. N., Friedman, D. B., Chan, J. Y., Meredith, M. J., et al. (2003). NADPH oxidase activity is essential for Keap1/Nrf2-mediated induction of GCLC in response to 2-indol-3-yl- methylenequinuclidin-3-ols. Cancer Research, 63, 5636-5645. (Pubitemid 37139889)
31. Lee, S. E., Jeong, S. I., Kim, G. D., Yang, H., Park, C. S., Jin, Y. H., et al. (2011). Upregulation of heme oxygenase-1 as an adaptive mechanism for protection against crotonaldehyde in human umbilical vein endothelial cells. Toxicology Letters, 201, 240-248.
32. Kim, Y. S., Pi, S. H., Lee, Y. M., Lee, S. I., & Kim, E. C. (2009). The anti-inflammatory role of heme oxygenase-1 in lipopolysaccharide and cytokine-stimulated inducible nitric oxide synthase and nitric oxide production in human periodontal ligament cells. Journal of Periodontology, 80, 2045-2055.
33. Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007). Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annual Review of Pharmacology and Toxicology, 47, 89-116.
34. Zimmerman, H. J., & Henry, J. B. (1988). Clinical diagnosis and management by laboratory methods. In J. B. Henry (Ed.), Clinical enzymology (pp. 251-258). Philadelphia, PA: The W.B. Saunders Company.
35. Lee, S. E., Yang, H., Jeong, S. I., Jin, Y. H., Park, C. S., & Park, Y. S. (2012). Induction of heme oxygenase-1 inhibits cell death in crotonaldehyde-stimulated HepG2 cells via the PKC-delta-p38-Nrf2 pathway. PLoS ONE, 7, e41676.
36. Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., et al. (2009). Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care, 32, 1224-1230.
37. Stroheker, T., Picard, K., Lhuguenot, J. C., Canivenc-Lavier, M. C., & Chagnon, M. C. (2004). Steroid activities comparison of natural and food wrap compounds in human breast cancer cell lines. Food and Chemical Toxicology, 42, 887-897. (Pubitemid 38515773)
38. Saad, S. Y., Najjar, T. A., & Alashari, M. (2004). Cardiotoxicity of doxorubicin/paclitaxel combination in rats: Effect of sequence and timing of administration. Journal of Biochemical and Molecular Toxicology, 18, 78-86. (Pubitemid 38607679)
39. Adamcova, M., Simunek, T., Kaiserova, H., Popelova, O., Sterba, M., Potacova, A., et al. (2007). In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology, 237, 218-228. (Pubitemid 47031418)
40. Noel, S., Sharma, S., Shanker, R., & Rath, S. K. (2007). Primaquine-induced differential gene expression analysis in mice liver using DNA microarrays. Toxicology, 239, 96-107. (Pubitemid 47284616)